Hodgkin's disease (HD) is often described as a lymphoid disorder associated with T cell hyporesponsiveness even in the early stages of the disease (Kaplan, 1981 ; Kumar & Penny, 1982) . Our earlier studies revealed that HD patients had normal levels of T and B cells in circulation, while they exhibited decreased mitogen (PHA) responsiveness as assessed by 3H-TdR incorporation as well as by T cell colony formation (Moghe et al., 1980; Mukhopadhyaya et al., 1983) . Activated lymphocytes from HD patients showed reduced levels of Tac + cells and reduced IL-2 production (Joshi et al., 1987; Mukhopadhyaya et al., 1987a) . However, upon addition of exogenous IL-2, lymphocytes from about half of the HD patients showed an increase in 3H-TdR incorporation but none showed an increase in T cell colony formation (Mukhopadhyaya et al., 1987b) . Other investigators have also reported similar abnormalities in IL-2 mediated events in T cell activation in HD (Ford et al., 1984; Soulillou et al., 1985; Zamkoff et al., 1985) .
The biological effect of IL-2 depends upon its binding to high affinity (HA) IL-2 receptors (IL-2R) on the membranes of activated cells, and internalisation of the complex (Fujii et al., 1986; Lowenthal & Greene, 1987; Robb & Gfeene, 1987) .
It is now well documented that IL-2R has a double chain molecular structure. The 13 chain (a Tac molecule) of M, 55,000 has a low affinity for IL-2 (Kd10-8M) and displays a fast rate of association and dissociation. The a-chain of Mr 75,000 with intermediate affinity (Kd-5 x 10-10 to 10-9M) has a slower rate of association and dissociation. A noncovalent association of these two chains makes a high affinity receptor (Kd-10-IlM) capable of signal transduction (Wang & Smith, 1987; Lowenthal & Greene, 1987) . Although the Tac molecule (p chain) is the first to interact with IL-2, this interaction does not induce internalisation of the complex, a prerequisite for signal transduction.
In case of HD, the evidence gathered so far suggests that, although the proportion of Tac + cells is less in activated lymphocyte populations in HD, the deficit is not proportional to the pronouned defect in the proliferative responses (Mukhopadhyaya et al., 1987a) . Also, addition of exogenous IL-2 did not restore fully the ability of the lymphocytes to proliferate and to form colonies (Mukhopadhyaya et al., 1987b) . It stages and grades of the diseases were included in the studies. Laboratory personnel (age group 20-35 years) constituted the control group. PBL were separated on a Ficoll-Hypaque gradient, washed and cultured in DMEM (Gibco) supplemented with antibiotics and 10% human blood group AB serum. Cells (2.5 x 106ml-') were stimulated with 0.5% PHA-M (Gibco, v/v) for 72 h at 37C in a humidified 5% CO2 atmosphere. The blasts thus obtained were used for further studies.
Recombinant IL-2 was labelled with 125I (Amersham, UK) by the method described by Robb et al. (1985) , with some modifications. IL-2, Na'251I and chloramaine-T were used at the molar ratios of 1:27.8:5.1. The reaction was carried out at room temperature for 5 min and was stopped using Na2S205 (0.278 mM). Free iodine was separated from '251I-IL-2 on a Sephadex G25 column, eluted with phosphate buffered saline containing 0.1% BSA and 1.5% acetic acid (final pH 3.9).
'25I-IL-2 with specific activity above 20,000 c.p.m. ng-1 was used for the experiments. Specificity of binding of '251-IL-2 was tested by assessing the radioactivity bound to PHA induced blasts from PBL of two healthy donors as a function of cell number and also by determining the inhibition of binding of '25I-IL-2 by increasing amounts of unlabelled IL-2 (Figure 1 ). The bioactivity of '251-IL-2 was assessed by its capacity to induce proliferation of CTLL (Gillis et al., 1978) . Proliferation of CTLL induced by '251I-IL-2 was 70-80% of that induced by unlabelled For experiments proper, the 251I-IL-2 binding assay was performed on PHA transformed blasts from PBL of HD patients and healthy donors, as described earlier (Fujii et al., 1986) . Non-specific binding was determined in the presence of 100-fold molar excess of unlabelled IL-2 and was subtracted before transforming the binding data into Scatchard plots. Dissociation constants (Kd) and number of receptors per cell were estimated from the Scatchard plots. Wherever possible, quantitation of PHA induced blasts (using Giemsa stained cytospin smears) and cell proliferation using 3H-TdR incorporation were studied simultaneously in order to compare the data with the IL-2R status.
The results indicated that lymphocytes from HD patients show significantly lower PHA induced proliferation and per cent blast formation as compared to lymphocytes from healthy donors (Table I) , while, as reported earlier (Joshi et al. 1987) , the percentage of Tac + cells in PHA activated HD PBL was 42.3 ± 11.2 (P<0.05) as compared to the value for healthy donors of 52.2 ± 14.1. The number and affinity of LA IL-2R on PHA blasts of HD patients and healthy donors were comparable (Table I) . It was interesting to note that the Kd value, which indicates half the maximal concentration of the ligand (IL-2) for saturation of the receptors, was significantly higher for HA IL-2R in HD patients than for HA IL-2R in healthy donors. The requirement for higher concentration of IL-2 reflects the lower affinity of the receptors for the ligand. However, the number of receptors per cell did not differ significantly between these two groups.
In a few patients and healthy donors, where we have been able to investigate proliferation and '25I-IL-2 binding simul- (Romagnani et al., 1985) may influence the IL-2R status of activated PBL in this disease. However, our earlier data and those of others (Gulwani et al., 1985; Posner et al., 1981) Our observations indicate the possibility of structural heterogeneity in HA IL-2R leading to T cell functional defects in HD. It is possible that a post-binding event such as internalisation of IL-2 and IL-2 complex leading to signal transduction (Fujii et al., 1986; Robb & Greene, 1987 ) may be abnormal in such situations. We are currently conducting studies on internalisation of '25I-IL-2 by activated PBL from HD in comparison with that by activated PBL from healthy donors, which may shed some light on this possibility.
